Mipasetamab
Mipasetamab Basic information
- Product Name:
- Mipasetamab
- Synonyms:
-
- Mipasetamab
- Research Grade Mipasetamab (DHD89503)
- Research Grade Mipasetamab
- Mipasetamab (anti-AXL)
- CAS:
- 2361055-48-1
- MW:
- 0
- Mol File:
- Mol File
Mipasetamab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Mipasetamab Usage And Synthesis
Uses
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity[1].
in vivo
ADCT-601 (3 mg/kg, 6 mg/kg; i.v.; single dose) is safety and tolerability in non-tumor-bearing male Sprague-Dawley rats[1].
ADCT-601 (1 mg/kg; i.v.; once daily for 60 days) shows potent and sustained antitumor activity for mouse in both MDA-MB-231 TNBC xenograft model and SN12C renal cancer xenograft model[1].
ADCT-601 (0.075, 0.15, or 0.3 mg/kg; i.v.; once daily for 45 days) also dose-dependently in a pancreatic cancer PDX model (PAXF1657) with heterogeneous AXL expression[1].
| Animal Model: | Mouse model with SN12C renal cancer xenograft or MDA-MB-231 TNBC xenograft[1] |
| Dosage: | 0.3, 0.6, and 1 mg/kg |
| Administration: | Intravenous injection; once daily for 60 days |
| Result: | Significantly inhibited the growth of tumor volume in vivo in mouse. |
IC 50
Axl
References
[1] Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593. DOI:10.1158/1535-7163.MCT-21-0715
MipasetamabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
Mipasetamab(2361055-48-1)Related Product Information
- Immunoglobulin G1,anti-(human CD19 (antigen)) (mouse monoclonal B43 g1-chain), disulfide with mouse monoclonal B43 k-chain, dimer, disulfide withprotein PAP (pokeweed antiviral) (9CI)
- Relfovetmab
- Immunoglobulin G2/G4, anti-(human complement C5) (human-Mus musculus ALXN1210 heavy chain), disulfide with human-Mus musculus ALXN1210 κ-chain, dimer
- Indatuximab Ravtansine
- Idarucizumab
- Atoltivimab
- Denintuzumab
- Tavolimab
- Glenzocimab
- Detumomab